{
  "id": 5082956,
  "title": "BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery",
  "url": "https://urgent.news/2026/09/02/benchsci-announces-two-year-enterprise-agreement-with-argenx-to",
  "topic": "ai",
  "section": "AI",
  "published": "2026-09-02T12:05:01.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/benchsci-announces-two-year-enterprise-agreement-with-argenx-to-advance-ai-driven-preclinical-drug-discovery"
  },
  "original_language": "en",
  "account": null,
  "summary": "Scientist-led competitive selection deepens BenchSci’s presence in European biopharma TORONTO — BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci’s agentic research environment for preclinical drug discovery, within the organization.…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}